-3 RECOMBINANT ADENOVIRAL VECTOR EXPRESSING CANINE INTERFERON LAMBDA-3
The present invention provides a recombinant adenoviral vector expressing canine interferon lambda-3. A recombinant target protein obtained by cells transformed with the vector has an excellent inhibitory effect against canine influenza virus, and thus can be used as a pharmaceutical composition for the treatment of diseases caused by viruses including canine influenza virus..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 27. Dez. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
CHOI IN SOO [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-27, Last update posted on www.tib.eu: 2023-12-20, Last updated: 2023-12-29 |
---|
Patentnummer: |
KR20220169275 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA016436695 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA016436695 | ||
003 | DE-627 | ||
005 | 20231229110938.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230607s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA016436695 | ||
035 | |a (EPA)KR20220169275 | ||
035 | |a (EPA)84568005 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a CHOI IN SOO |e verfasserin |4 aut | |
245 | 1 | 0 | |a -3 RECOMBINANT ADENOVIRAL VECTOR EXPRESSING CANINE INTERFERON LAMBDA-3 |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-27, Last update posted on www.tib.eu: 2023-12-20, Last updated: 2023-12-29 | ||
520 | |a The present invention provides a recombinant adenoviral vector expressing canine interferon lambda-3. A recombinant target protein obtained by cells transformed with the vector has an excellent inhibitory effect against canine influenza virus, and thus can be used as a pharmaceutical composition for the treatment of diseases caused by viruses including canine influenza virus. | ||
650 | 4 | |a bio | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a KIM DONG HWI |4 aut | |
700 | 0 | |a GO HYEON JEONG |4 aut | |
700 | 0 | |a AHN HEE SEOP |4 aut | |
700 | 0 | |a KIM DAYOON |4 aut | |
700 | 0 | |a KIM JAEHYEONG |4 aut | |
700 | 0 | |a PARK BYUNGJOO |4 aut | |
700 | 0 | |a PARK SEUNG YONG |4 aut | |
700 | 0 | |a SONG CHANG SEON |4 aut | |
700 | 0 | |a SANG WON LEE |4 aut | |
700 | 0 | |a JOONG BOK LEE |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 27. Dez. |
773 | 1 | 8 | |g year:2022 |g day:27 |g month:12 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84568005/publication/KR20220169275A1?q=KR20220169275 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2022 |b 27 |c 12 |
951 | |a AR | ||
952 | |j 2022 |b 27 |c 12 |